Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Lancet
    February 2024
  1. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    >> Share

  2. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    >> Share

    January 2024
  3. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    >> Share

  4. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    >> Share

    November 2023
  5. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    >> Share

  6. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    >> Share

  7. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    >> Share

  8. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

    October 2023
  9. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    >> Share

  10. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    >> Share

  11. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    >> Share

    September 2023
  12. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    >> Share

  13. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    >> Share

  14. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    >> Share

    August 2023
  15. LAFAYETTE R, Kristensen J, Stone A, Floege J, et al
    Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lancet. 2023 Aug 14:S0140-6736(23)01554-4. doi: 10.1016/S0140-6736(23)01554.
    >> Share

  16. HARALDSSON B
    Phase 3 trial results bring hope for patients with IgA nephropathy.
    Lancet. 2023 Aug 14:S0140-6736(23)01633-1. doi: 10.1016/S0140-6736(23)01633.
    >> Share

  17. RAMANAN AV, Quartier P, Okamoto N, Foeldvari I, et al
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023;402:555-570.
    >> Share

    July 2023
  18. RIFE EC, Cron RQ
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Jul 6:S0140-6736(23)01134-0. doi: 10.1016/S0140-6736(23)01134.
    >> Share

    June 2023

  19. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    >> Share

  20. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    >> Share

    May 2023
  21. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    >> Share

  22. WEN X, Li B
    A population-based study on autoimmune disease.
    Lancet. 2023 May 5:S0140-6736(23)00621-9. doi: 10.1016/S0140-6736(23)00621.
    >> Share

    April 2023
  23. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    >> Share

    March 2023
  24. LUNDBERG S, Bergen K
    We can go further in non-immunosuppressive treatment of IgA nephropathy.
    Lancet. 2023 Mar 31:S0140-6736(23)00630-X. doi: 10.1016/S0140-6736(23)00630.
    >> Share

  25. HEERSPINK HJL, Radhakrishnan J, Alpers CE, Barratt J, et al
    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Lancet. 2023 Mar 31:S0140-6736(23)00569-X. doi: 10.1016/S0140-6736(23)00569.
    >> Share

  26. DURCAN L, Murphy G
    SLE-BRAVE I and II.
    Lancet. 2023;401:972-973.
    >> Share

  27. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    >> Share

    February 2023
  28. PETRI M, Bruce IN, Dorner T, Tanaka Y, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Lancet. 2023 Feb 24:S0140-6736(22)02546-6. doi: 10.1016/S0140-6736(22)02546.
    >> Share

  29. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    >> Share

    January 2023
  30. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    >> Share

  31. GUGER M, Ransmayr G, Sonnberger M, Hametner S, et al
    Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia.
    Lancet. 2023;401:226.
    >> Share

  32. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    >> Share

  33. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    >> Share

  34. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    >> Share

    December 2022
  35. HEBBINK JA, Nobels-Janssen E, Verhagen I, Kusters B, et al
    Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome.
    Lancet. 2022;400:1966.
    >> Share

    October 2022
  36. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    >> Share

    August 2022
  37. RIDKER PM
    Autoimmune diseases and atherothrombotic risk.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.
    >> Share

  38. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    >> Share

    May 2022
  39. RUPERTO N, Brunner HI, Posner HB, Lazariciu I, et al
    Tofacitinib for juvenile idiopathic arthritis - Authors' reply.
    Lancet. 2022;399:1866.
    >> Share

  40. MURRAY GM, Renton WD
    Tofacitinib for juvenile idiopathic arthritis.
    Lancet. 2022;399:1865-1866.
    >> Share

    April 2022
  41. SETHI S, De Vriese AS, Fervenza FC
    Acute glomerulonephritis.
    Lancet. 2022;399:1646-1663.
    >> Share

  42. PRASAD A
    Angela Migowa: advocating for children with rheumatic diseases.
    Lancet. 2022;399:1294.
    >> Share

    March 2022
  43. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    >> Share

    January 2022
  44. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    >> Share

    November 2021
  45. CLARKE SLN, Ramanan AV
    Tofacitinib in juvenile idiopathic arthritis.
    Lancet. 2021;398:1943-1945.
    >> Share

  46. RUPERTO N, Brunner HI, Synoverska O, Ting TV, et al
    Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Lancet. 2021;398:1984-1996.
    >> Share

  47. LODGE FM, Moody WE, Tosounidou S, Chue CD, et al
    Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
    Lancet. 2021;398:1913.
    >> Share

  48. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    >> Share

  49. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    >> Share

  50. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    >> Share

  51. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    >> Share

    October 2021
  52. CHEN LYC, Slack GW, Carruthers MN
    IgG4-related disease and Rosai-Dorfman-Destombes disease.
    Lancet. 2021;398:1213-1214.
    >> Share

  53. EMILE JF, Vaglio A, Cohen-Aubart F, Haroche J, et al
    IgG4-related disease and Rosai-Dorfman-Destombes disease - Authors' reply.
    Lancet. 2021;398:1214-1215.
    >> Share

    August 2021
  54. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    >> Share

    July 2021
  55. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    >> Share

  56. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.
    >> Share

    June 2021
  57. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    >> Share

  58. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    >> Share

  59. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.
    >> Share

  60. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    >> Share

    May 2021
  61. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    >> Share

  62. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.
    >> Share

    April 2021
  63. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    >> Share

  64. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    >> Share

    October 2020
  65. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016